ArticleJournal of menopausal medicine2025
Partially Absorbable Mesh (SERATOM
Article in Journal of menopausal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis prospective multi-center pilot study evaluated the safety, efficacy, and quality of life (QoL) outcomes associated with the use of a transvaginal mesh kit utilizing partially absorbable mesh (PAM) in Korean women with pelvic organ prolapse (POP).
methodsThirty patients with symptomatic POP stage II or higher underwent surgical repair using the SERATOM
resultsThe mean participant age was 65.6 years, with 97% being postmenopausal. Preoperative POP-Q staging revealed that most patients (87%) had stage III or IV prolapse. The average surgical time was 96.4 minutes, and hospital stay averaged 4.9 days. No intraoperative or postoperative complications were reported. Of the 24 patients who completed follow-up, 23 achieved POP-Q stage 0 at six months, with the remaining patient at stage I but asymptomatic, requiring no further intervention. No cases of healing abnormalities or reoperations were noted. Significant improvements in pelvic floor dysfunction symptoms and sexual function were observed, as evidenced by marked improvements in PFDI-20, PFIQ-7, and PISQ-12 scores at six months postoperatively.
conclusionsThe use of PAM in transvaginal POP surgery demonstrated high efficacy, excellent safety outcomes, and significant improvement in QoL, suggesting it is a viable surgical option for advanced POP in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.